Symbols / PSTV
PSTV Chart
About
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company's lead radiotherapeutic candidate is REYOBIQ, a patented radiotherapy for patients with central nervous system and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere to treat various solid organ cancers, such as primary and secondary liver cancers by intra-arterial injection. In addition, it develops and commercializes laboratory-developed tests, such as the CNSide Test to identify tumor cells that have metastasized to the central nervous system in patients with carcinomas and melanomas. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Houston, Texas.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 59.99M |
| Enterprise Value | 28.30M | Income | -20.58M | Sales | 5.26M |
| Book/sh | 0.04 | Cash/sh | 0.12 | Dividend Yield | — |
| Payout | 0.00% | Employees | 21 | IPO | — |
| P/E | — | Forward P/E | -2.29 | PEG | — |
| P/S | 11.41 | P/B | 8.85 | P/C | — |
| EV/EBITDA | -2.18 | EV/Sales | 5.38 | Quick Ratio | 1.22 |
| Current Ratio | 1.29 | Debt/Eq | 127.05 | LT Debt/Eq | — |
| EPS (ttm) | -0.96 | EPS next Y | -0.15 | EPS Growth | — |
| Revenue Growth | -4.10% | Earnings | 2026-03-04 | ROA | -65.58% |
| ROE | — | ROIC | — | Gross Margin | -45.00% |
| Oper. Margin | -3.21% | Profit Margin | 0.00% | Shs Outstand | 178.37M |
| Shs Float | 127.33M | Short Float | 13.49% | Short Ratio | 1.39 |
| Short Interest | — | 52W High | 2.31 | 52W Low | 0.16 |
| Beta | 0.85 | Avg Volume | 9.77M | Volume | 10.20M |
| Target Price | $5.50 | Recom | None | Prev Close | $0.28 |
| Price | $0.34 | Change | 20.11% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$5.50
Mean price target
2. Current target
$0.34
Latest analyst target
3. DCF / Fair value
$-0.94
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.34
Low
$1.00
High
$19.00
Mean
$5.50
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-01-23 | main | HC Wainwright & Co. | Buy → Buy | $1 |
| 2026-01-22 | main | D. Boral Capital | Buy → Buy | $4 |
| 2026-01-08 | main | D. Boral Capital | Buy → Buy | $5 |
| 2025-12-11 | main | D. Boral Capital | Buy → Buy | $5 |
| 2025-12-01 | main | D. Boral Capital | Buy → Buy | $5 |
| 2025-11-21 | main | Ascendiant Capital | Buy → Buy | $19 |
| 2025-11-20 | main | D. Boral Capital | Buy → Buy | $5 |
| 2025-11-03 | main | HC Wainwright & Co. | Buy → Buy | $2 |
| 2025-10-31 | main | D. Boral Capital | Buy → Buy | $5 |
| 2025-10-21 | main | D. Boral Capital | Buy → Buy | $5 |
| 2025-10-06 | main | Ascendiant Capital | Buy → Buy | $21 |
| 2025-09-25 | main | D. Boral Capital | Buy → Buy | $5 |
| 2025-09-22 | main | D. Boral Capital | Buy → Buy | $5 |
| 2025-09-18 | main | D. Boral Capital | Buy → Buy | $5 |
| 2025-09-03 | up | D. Boral Capital | Hold → Buy | $5 |
| 2025-08-18 | main | Maxim Group | Buy → Buy | $3 |
| 2025-06-27 | main | HC Wainwright & Co. | Buy → Buy | $3 |
| 2025-06-25 | main | D. Boral Capital | Hold → Hold | $9 |
| 2025-06-05 | main | Ascendiant Capital | Buy → Buy | $21 |
| 2025-05-05 | down | D. Boral Capital | Buy → Hold | — |
- New AMA code tracks REYOBIQ therapy in aggressive brain cancers - Stock Titan Wed, 25 Feb 2026 12
- $PSTV stock is down 9% today. Here's what we see in our data. - Quiver Quantitative hu, 22 Jan 2026 08
- Plus Therapeutics (PSTV) Sees Price Target Cut by HC Wainwright | PSTV Stock News - GuruFocus Fri, 23 Jan 2026 08
- PSTV Plunges On $15 Mln Upsized Offering - Nasdaq Wed, 14 Jan 2026 08
- Plus Therapeutics (PSTV) Reports Q3 Loss, Lags Revenue Estimates - Yahoo Finance hu, 30 Oct 2025 07
- CNS cancer-focused company raises $15M in stock and warrant sale - Stock Titan Wed, 14 Jan 2026 08
- Plus Therapeutics (PSTV) Soars 40% as Firm Seals Partnership with United Healthcare - Yahoo Finance Fri, 26 Sep 2025 07
- D. Boral Capital Maintains Plus Therapeutics (PSTV) Buy Recommendation - Nasdaq hu, 11 Dec 2025 08
- Plus Therapeutics (Nasdaq: PSTV) expands CNSide team and issues new hire equity awards - Stock Titan ue, 09 Dec 2025 08
- Plus Therapeutics Stock (PSTV) Opinions on Humana Coverage Agreement - Quiver Quantitative Sun, 23 Nov 2025 08
- Plus Therapeutics (Nasdaq: PSTV) CNSide test now licensed in 48 states, reaching over 90% of U.S. - Stock Titan hu, 11 Dec 2025 08
- $PSTV stock is down 7% today. Here's what we see in our data. - Quiver Quantitative Mon, 03 Nov 2025 08
- Plus Therapeutics (Nasdaq: PSTV) gets 180-day extension to meet $1 Nasdaq bid price - Stock Titan Mon, 17 Nov 2025 08
- Plus Therapeutics Stock (PSTV) Opinions on UnitedHealthcare Coverage Deal - Quiver Quantitative ue, 21 Oct 2025 07
- Plus Therapeutics Stock (PSTV) Opinions on UnitedHealthcare Coverage Agreement - Quiver Quantitative hu, 06 Nov 2025 08
Insider Transactions
| Date | Shares | Url | Text | Insider | Position | Transaction | Start Date | Ownership | Value |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 159681 | — | — | HEDRICK MARC HAMILTON | Chief Executive Officer | — | 2025-12-31 00:00:00 | D | nan |
| 1 | 38323 | — | — | SIMS ANDREW JOHN HUGH MACINTYRE | Chief Financial Officer | — | 2025-12-31 00:00:00 | D | nan |
| 2 | 20000 | — | Purchase at price 0.51 per share. | SIMS ANDREW JOHN HUGH MACINTYRE | Chief Financial Officer | — | 2025-11-04 00:00:00 | D | 10200.0 |
| 3 | 159681 | — | — | HEDRICK MARC HAMILTON | Chief Executive Officer | — | 2025-10-01 00:00:00 | D | nan |
| 4 | 38323 | — | — | SIMS ANDREW JOHN HUGH MACINTYRE | Chief Financial Officer | — | 2025-10-01 00:00:00 | D | nan |
| 5 | 110000 | — | Purchase at price 0.49 per share. | LENK ROBERT P | Director | — | 2025-08-22 00:00:00 | D | 53779.0 |
| 6 | 4000 | — | Purchase at price 1.50 per share. | HAWKINS RICHARD JAMES | Director | — | 2024-09-13 00:00:00 | D | 5996.0 |
| 7 | 6285 | — | Purchase at price 1.35 per share. | HAWKINS RICHARD JAMES | Director | — | 2024-09-12 00:00:00 | D | 8512.0 |
| 8 | 5000 | — | Purchase at price 1.34 per share. | CLOWES HOWARD | Director | — | 2024-09-11 00:00:00 | D | 6681.0 |
| 9 | 12500 | — | Purchase at price 1.35 per share. | PETERSEN GREGORY B | Director | — | 2024-09-11 00:00:00 | D | 16875.0 |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -13.70M | -12.29M | -18.95M | -12.01M |
| TotalUnusualItems | 5.17M | 1.00K | -60.00K | |
| TotalUnusualItemsExcludingGoodwill | 5.17M | 1.00K | -60.00K | |
| NetIncomeFromContinuingOperationNetMinorityInterest | -12.98M | -13.32M | -20.27M | -13.40M |
| ReconciledDepreciation | 723.00K | 628.00K | 619.00K | 395.00K |
| EBITDA | -8.53M | -12.29M | -18.95M | -12.07M |
| EBIT | -9.25M | -12.92M | -19.56M | -12.47M |
| NetInterestIncome | -3.45M | 5.00K | -564.00K | -913.00K |
| InterestExpense | 3.72M | 395.00K | 711.00K | 932.00K |
| InterestIncome | 273.00K | 400.00K | 147.00K | 19.00K |
| NormalizedIncome | -18.15M | -13.32M | -20.27M | -13.34M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -12.98M | -13.32M | -20.27M | -13.40M |
| TotalExpenses | 14.70M | 13.32M | 19.71M | 12.43M |
| TotalOperatingIncomeAsReported | -14.70M | -13.32M | -19.71M | -12.49M |
| DilutedAverageShares | 7.70M | 3.14M | 1.75M | 805.95K |
| BasicAverageShares | 6.64M | 3.14M | 1.75M | 805.95K |
| DilutedEPS | -2.34 | -4.24 | -11.55 | -16.65 |
| BasicEPS | -1.95 | -4.24 | -11.55 | -16.65 |
| DilutedNIAvailtoComStockholders | -12.98M | -13.32M | -20.27M | -13.40M |
| NetIncomeCommonStockholders | -12.98M | -13.32M | -20.27M | -13.40M |
| NetIncome | -12.98M | -13.32M | -20.27M | -13.40M |
| NetIncomeIncludingNoncontrollingInterests | -12.98M | -13.32M | -20.27M | -13.40M |
| NetIncomeContinuousOperations | -12.98M | -13.32M | -20.27M | -13.40M |
| PretaxIncome | -12.98M | -13.32M | -20.27M | -13.40M |
| OtherIncomeExpense | 5.17M | 1.00K | -60.00K | |
| OtherNonOperatingIncomeExpenses | -486.00K | 1.00K | 6.00K | |
| SpecialIncomeCharges | 0.00 | -66.00K | ||
| GainOnSaleOfPPE | 0.00 | -66.00K | ||
| GainOnSaleOfSecurity | 5.17M | 1.00K | 6.00K | |
| NetNonOperatingInterestIncomeExpense | -3.45M | 5.00K | -564.00K | -913.00K |
| InterestExpenseNonOperating | 3.72M | 395.00K | 711.00K | 932.00K |
| InterestIncomeNonOperating | 273.00K | 400.00K | 147.00K | 19.00K |
| OperatingIncome | -14.70M | -13.32M | -19.71M | -12.43M |
| OperatingExpense | 14.70M | 13.32M | 19.71M | 12.43M |
| OtherOperatingExpenses | -5.82M | -4.91M | -224.00K | |
| ResearchAndDevelopment | 10.58M | 9.69M | 9.70M | 5.57M |
| SellingGeneralAndAdministration | 9.94M | 8.54M | 10.24M | 6.85M |
| GeneralAndAdministrativeExpense | 9.94M | 8.54M | 10.24M | 6.85M |
| OtherGandA | 9.94M | 8.54M | 10.24M | 6.85M |
| SalariesAndWages | 519.00K | 531.00K | ||
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | ||
|---|---|---|---|---|
| TreasurySharesNumber | 258.43K | 78.56K | ||
| PreferredSharesNumber | 325.00 | 325.00 | 325.00 | 325.00 |
| OrdinarySharesNumber | 5.90M | 4.44M | 2.24M | 1.03M |
| ShareIssued | 6.15M | 4.52M | 2.24M | 1.03M |
| NetDebt | 3.22M | |||
| TotalDebt | 3.37M | 4.18M | 5.64M | 6.99M |
| TangibleBookValue | -9.79M | -1.76M | 5.98M | 10.41M |
| InvestedCapital | -5.66M | 2.63M | 11.84M | 17.45M |
| WorkingCapital | -10.29M | -893.00K | 9.96M | 13.85M |
| NetTangibleAssets | -9.79M | -1.76M | 5.98M | 10.41M |
| CapitalLeaseObligations | 75.00K | 205.00K | 251.00K | 380.00K |
| CommonStockEquity | -8.95M | -1.35M | 6.45M | 10.84M |
| TotalCapitalization | -8.95M | -1.35M | 10.23M | 15.84M |
| TotalEquityGrossMinorityInterest | -8.95M | -1.35M | 6.45M | 10.84M |
| StockholdersEquity | -8.95M | -1.35M | 6.45M | 10.84M |
| TreasuryStock | 500.00K | 126.00K | 0.00 | |
| RetainedEarnings | -493.48M | -480.50M | -467.19M | -446.91M |
| AdditionalPaidInCapital | 485.02M | 479.27M | 473.63M | 457.73M |
| CapitalStock | 6.00K | 5.00K | 2.00K | 16.00K |
| CommonStock | 6.00K | 5.00K | 2.00K | 16.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 15.58M | 12.74M | 17.42M | 11.14M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 31.00K | 2.01M | 5.57M | 5.28M |
| DerivativeProductLiabilities | 0.00 | 1.00K | ||
| NonCurrentDeferredLiabilities | 0.00 | 1.92M | 1.64M | 0.00 |
| NonCurrentDeferredRevenue | 0.00 | 1.92M | 1.64M | |
| LongTermDebtAndCapitalLeaseObligation | 31.00K | 85.00K | 3.93M | 5.27M |
| LongTermCapitalLeaseObligation | 31.00K | 85.00K | 141.00K | 269.00K |
| LongTermDebt | 3.79M | 5.00M | ||
| CurrentLiabilities | 15.55M | 10.73M | 11.85M | 5.87M |
| OtherCurrentLiabilities | 122.00K | |||
| CurrentDeferredLiabilities | 927.00K | 0.00 | ||
| CurrentDeferredRevenue | 927.00K | 0.00 | ||
| CurrentDebtAndCapitalLeaseObligation | 3.34M | 4.10M | 1.72M | 1.72M |
| CurrentCapitalLeaseObligation | 44.00K | 120.00K | 110.00K | 111.00K |
| CurrentDebt | 3.29M | 3.98M | 1.61M | 1.61M |
| OtherCurrentBorrowings | 3.98M | 1.61M | 1.61M | |
| LineOfCredit | 3.29M | 3.98M | ||
| PensionandOtherPostRetirementBenefitPlansCurrent | 356.00K | 370.00K | 325.00K | 252.00K |
| PayablesAndAccruedExpenses | 10.93M | 6.26M | 9.81M | 3.78M |
| CurrentAccruedExpenses | 1.46M | 1.50M | 1.45M | 1.17M |
| InterestPayable | 117.00K | 0.00 | ||
| Payables | 9.47M | 4.76M | 8.36M | 2.61M |
| AccountsPayable | 9.47M | 4.76M | 8.36M | 2.61M |
| TotalAssets | 6.63M | 11.39M | 23.87M | 21.98M |
| TotalNonCurrentAssets | 1.37M | 1.55M | 2.05M | 2.26M |
| OtherNonCurrentAssets | 12.00K | 32.00K | 12.00K | 16.00K |
| GoodwillAndOtherIntangibleAssets | 841.00K | 414.00K | 466.00K | 423.00K |
| OtherIntangibleAssets | 469.00K | 42.00K | 94.00K | 51.00K |
| Goodwill | 372.00K | 372.00K | 372.00K | 372.00K |
| NetPPE | 521.00K | 1.11M | 1.57M | 1.82M |
| AccumulatedDepreciation | -3.14M | -2.54M | -1.96M | -1.42M |
| GrossPPE | 3.66M | 3.64M | 3.53M | 3.23M |
| Leases | 1.81M | 1.81M | 1.81M | 1.66M |
| OtherProperties | 73.00K | 202.00K | 248.00K | 341.00K |
| MachineryFurnitureEquipment | 1.78M | 1.63M | 1.47M | 1.23M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 5.26M | 9.83M | 21.82M | 19.72M |
| OtherCurrentAssets | 7.00K | |||
| CurrentDeferredAssets | 436.00K | 234.00K | ||
| PrepaidAssets | 646.00K | 1.05M | 3.70M | 1.32M |
| Receivables | 571.00K | 0.00 | 7.00K | |
| OtherReceivables | 571.00K | 7.00K | ||
| CashCashEquivalentsAndShortTermInvestments | 3.61M | 8.55M | 18.12M | 18.40M |
| OtherShortTermInvestments | 3.53M | 0.00 | ||
| CashAndCashEquivalents | 76.00K | 8.55M | 18.12M | 18.40M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -11.24M | -13.01M | -13.73M | -10.42M |
| RepurchaseOfCapitalStock | -374.00K | -126.00K | 0.00 | |
| RepaymentOfDebt | -4.00M | -1.61M | -1.61M | -276.00K |
| IssuanceOfDebt | 3.29M | 0.00 | ||
| IssuanceOfCapitalStock | 7.26M | 5.53M | 15.83M | 18.68M |
| CapitalExpenditure | -691.00K | -160.00K | -759.00K | -144.00K |
| InterestPaidSupplementalData | 32.00K | 222.00K | 327.00K | 388.00K |
| EndCashPosition | 76.00K | 8.55M | 18.12M | 18.40M |
| BeginningCashPosition | 8.55M | 18.12M | 18.40M | 8.35M |
| ChangesInCash | -8.48M | -9.57M | -280.00K | 10.05M |
| FinancingCashFlow | 6.19M | 3.44M | 13.45M | 20.42M |
| CashFlowFromContinuingFinancingActivities | 6.19M | 3.44M | 13.45M | 20.42M |
| NetOtherFinancingCharges | -348.00K | -773.00K | ||
| ProceedsFromStockOptionExercised | 0.00 | 2.02M | ||
| NetCommonStockIssuance | 6.89M | 5.40M | 15.83M | 18.68M |
| CommonStockPayments | -374.00K | -126.00K | 0.00 | |
| CommonStockIssuance | 7.26M | 5.53M | 15.83M | 18.68M |
| NetIssuancePaymentsOfDebt | -704.00K | -1.61M | -1.61M | -276.00K |
| NetShortTermDebtIssuance | 3.29M | 0.00 | ||
| ShortTermDebtIssuance | 3.29M | 0.00 | ||
| NetLongTermDebtIssuance | -4.00M | -1.61M | -1.61M | -276.00K |
| LongTermDebtPayments | -4.00M | -1.61M | -1.61M | -276.00K |
| InvestingCashFlow | -4.11M | -160.00K | -759.00K | -82.00K |
| CashFlowFromContinuingInvestingActivities | -4.11M | -160.00K | -759.00K | -82.00K |
| NetOtherInvestingChanges | -250.00K | |||
| NetInvestmentPurchaseAndSale | -3.42M | 0.00 | ||
| SaleOfInvestment | 12.17M | 0.00 | ||
| PurchaseOfInvestment | -15.59M | 0.00 | ||
| NetIntangiblesPurchaseAndSale | -545.00K | 0.00 | -250.00K | 0.00 |
| PurchaseOfIntangibles | -545.00K | 0.00 | -250.00K | 0.00 |
| NetPPEPurchaseAndSale | -146.00K | -160.00K | -509.00K | -82.00K |
| SaleOfPPE | 0.00 | 62.00K | ||
| PurchaseOfPPE | -146.00K | -160.00K | -509.00K | -144.00K |
| OperatingCashFlow | -10.55M | -12.85M | -12.97M | -10.28M |
| CashFlowFromContinuingOperatingActivities | -10.55M | -12.85M | -12.97M | -10.28M |
| ChangeInWorkingCapital | 3.22M | -1.12M | 5.60M | 1.24M |
| ChangeInOtherWorkingCapital | -997.00K | 281.00K | 1.64M | |
| ChangeInOtherCurrentLiabilities | -130.00K | -117.00K | -129.00K | 0.00 |
| ChangeInOtherCurrentAssets | 218.00K | 2.40M | -2.37M | -496.00K |
| ChangeInPayablesAndAccruedExpense | 4.70M | -3.68M | 6.45M | 1.73M |
| ChangeInReceivables | -571.00K | 0.00 | 0.00 | |
| ChangesInAccountReceivables | 0.00 | |||
| OtherNonCashItems | 3.69M | 382.00K | 388.00K | 790.00K |
| StockBasedCompensation | 550.00K | 569.00K | 606.00K | 606.00K |
| UnrealizedGainLossOnInvestmentSecurities | -1.00K | -6.00K | ||
| AssetImpairmentCharge | 117.00K | 93.00K | 24.00K | |
| AmortizationOfSecurities | -111.00K | 0.00 | ||
| DepreciationAmortizationDepletion | 723.00K | 628.00K | 619.00K | 395.00K |
| DepreciationAndAmortization | 723.00K | 628.00K | 619.00K | 395.00K |
| AmortizationCashFlow | 100.00K | 100.00K | 100.00K | |
| AmortizationOfIntangibles | 100.00K | 100.00K | 100.00K | |
| Depreciation | 600.00K | 600.00K | 500.00K | |
| OperatingGainsLosses | -5.65M | 2.00K | 66.00K | |
| GainLossOnInvestmentSecurities | -5.65M | |||
| GainLossOnSaleOfPPE | 0.00 | 2.00K | 0.00 | 66.00K |
| NetIncomeFromContinuingOperations | -12.98M | -13.32M | -20.27M | -13.40M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for PSTV
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|